Intracellular signaling pathways pave roads to recovery for mood disorders

References

• Kessler R. C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K. R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS‐R). JAMA 2003; 289: 3095–105
   PubMed Web of Science ®Google Scholar
• Wittchen H. U., Knauper B., Kessler R. C. Lifetime risk of depression. Br J Psychiatry Suppl 1994; 16–22
   Google Scholar
• Pincus H. A., Pettit A. R. The societal costs of chronic major depression. J Clin Psychiatry 2001; 62(Suppl 6)5–9
   PubMed Web of Science ®Google Scholar
• Stewart W. F., Ricci J. A., Chee E., Hahn S. R., Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003; 289: 3135–44
   PubMed Web of Science ®Google Scholar
• Greenberg P. E., Kessler R. C., Birnbaum H. G., Leong S. A., Lowe S. W., Berglund P. A., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003; 64: 1465–75
   PubMed Web of Science ®Google Scholar
• Murray C. J., Lopez A. D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504
   PubMed Web of Science ®Google Scholar
• Goodwin F., Jamison K. R. Manic Depressive Illness. Oxford University Press, New York 1990
   Google Scholar
• Nelson J. C. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999; 46: 1301–8
   Web of Science ®Google Scholar
• Wong M. L., Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136–51
   PubMed Web of Science ®Google Scholar
• Montgomery S. A. Why do we need new and better antidepressants?. Int Clin Psychopharmacol 2006; 21(Suppl 1)S1–10
   PubMedGoogle Scholar
• Geddes J. R., Burgess S., Hawton K., Jamison K., Goodwin G. M. Long‐term lithium therapy for bipolar disorder: systematic review and meta‐analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217–22
   PubMedGoogle Scholar
• Zarate C. A., Jr., Quiroz J. A. Combination treatment in bipolar disorder: a review of controlled trials. Bipolar Disord 2003; 5: 217–25
   PubMed Web of Science ®Google Scholar
• Mukherjee S., Sackeim H. A., Schnur D. B. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry 1994; 151: 169–76
   PubMed Web of Science ®Google Scholar
• D'Sa C., Duman R. S. Antidepressants and neuroplasticity. Bipolar Disord 2002; 4: 183–94
   PubMed Web of Science ®Google Scholar
• Yamada M., Higuchi T. Antidepressant‐elicited changes in gene expression Remodeling of neuronal circuits as a new hypothesis for drug efficacy. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 999–1009
   PubMedGoogle Scholar
• Duman R. S., Monteggia L. M. A neurotrophic model for stress‐related mood disorders. Biol Psychiatry 2006; 59: 1116–27
   PubMed Web of Science ®Google Scholar
• Manji H., Duman R. S. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull 2001; 35: 5–49
   PubMedGoogle Scholar
• Manji H. K., Drevets W. C., Charney D. S. The cellular neurobiology of depression. Nat Med 2001; 7: 541–7
   PubMed Web of Science ®Google Scholar
• Duman R. Depression: A case of neuronal life and death?. Biol Psychiatry 2004; 56: 140–45
   PubMed Web of Science ®Google Scholar
• Sheline Y., Gado M. H., Kraemer H. C. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516–8
   PubMed Web of Science ®Google Scholar
• Vermetten E., Vythilingam M., Southwick S. M., Charney D. S., Bremner J. D. Long‐term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 693–702
   PubMed Web of Science ®Google Scholar
• Moore G., Bebchuk J. M., Wilds I. B., Chen G., Manji H. K., Menji H. K. Lithium‐induced increase in human brain grey matter. Lancet 2000; 356: 1241–2
   PubMed Web of Science ®Google Scholar
• Drevets W. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813–29
   PubMed Web of Science ®Google Scholar
• Malberg J., Eisch A. J., Nestler E. J., Duman R. S. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci 2000; 20: 9104–10
   PubMed Web of Science ®Google Scholar
• Czeh B., Michaelis T., Watanabe T., Frahm J., de Biurrun G., van Kampen M., et al. Stress‐induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A 2001; 98: 12796–801
   PubMed Web of Science ®Google Scholar
• Madsen T., Treschow A., Bengzon J., Bolwig T. G., Lindvall O., Tingström A. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry 2000; 47: 1043–49
   PubMed Web of Science ®Google Scholar
• Manev H., Uz T., Smalheiser N. R., Manev R. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol 2001; 411: 67–70
   PubMed Web of Science ®Google Scholar
• Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., et al. Requirement of hippocampal neurogenisis for the behavioral effects of antidepressants. Science 2003; 301: 805–09
   PubMed Web of Science ®Google Scholar
• Chen G., Rajkowska G., Du F., Seraji‐Bozorgzad N., Manji H. K. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729–34
   PubMed Web of Science ®Google Scholar
• Perez J., Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R. Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disord 2000; 2: 27–36
   PubMed Web of Science ®Google Scholar
• Duman R. Novel therapeutic approaches beyond the serotonin receptor. Biol Psychiatry 1998; 44: 324–35
   PubMed Web of Science ®Google Scholar
• Adayev T., Ranasinghe B., Banerjee P. Transmembrane signaling in the brain by serotonin, a key regulator of physiology and emotion. Biosci Rep 2005; 25: 363–85
   PubMed Web of Science ®Google Scholar
• Zheng M., Zhu W., Han Q., Xiao R. P. Emerging concepts and therapeutic implications of beta‐adrenergic receptor subtype signaling. Pharmacol Ther 2005; 1083): 257–68
   Google Scholar
• Aantaa R., Marjamaki A., Scheinin M. Molecular pharmacology of alpha 2‐adrenoceptor subtypes. Ann Med 1995; 27((4))439–49
   Google Scholar
• Kamenetsky M., Middelhaufe S., Bank E. M., Levin L. R., Buck J., Steegborn C. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J Mol Biol 2006; 362: 623–39
   PubMed Web of Science ®Google Scholar
• Brandon E. P., Idzerda R. L., McKnight G. S. PKA isoforms, neural pathways, and behaviour: making the connection. Curr Opin Neurobiol 1997; 7: 397–403
   PubMedGoogle Scholar
• Nguyen P. V., Woo N. H. Regulation of hippocampal synaptic plasticity by cyclic AMP‐dependent protein kinases. Prog Neurobiol 2003; 71: 401–37
   Google Scholar
• Lonze B. E., Ginty D. D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 2002; 35: 605–23
   PubMed Web of Science ®Google Scholar
• Dyke H. J., Montana J. G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1–13
   PubMed Web of Science ®Google Scholar
• Houslay M. D., Schafer P., Zhang K. Y. Keynote review: phosphodiesterase‐4 as a therapeutic target. Drug Discov Today 2005; 10: 1503–19
   PubMed Web of Science ®Google Scholar
• Dowlatshahi D., MacQueen G. M., Wang J. F., Young L. T. Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 1998; 352: 1754–5
   Google Scholar
• Dowlatshahi D., MacQueen G. M., Wang J. F., Reiach J. S., Young L. T. G protein‐coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 1999; 73: 1121–6
   PubMed Web of Science ®Google Scholar
• Cowburn R. F., Marcusson J. O., Eriksson A., Wiehager B., O'Neill C. Adenylyl cyclase activity and G‐protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 1994; 633: 297–304
   Google Scholar
• Manier D., Eiring A., Shelton R. C., Sulser F. β‐Adrenoceptor‐linked protein Kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression. Neuropsychopharm 1996; 15: 556–61
   Google Scholar
• Manier D. H., Shelton R. C., Ellis T. C., Peterson C. S., Eiring A., Sulser F. Human fibroblasts as a relevant model to study signal transduction in affective disorders. J Affect Disord 2000; 61: 51–8
   PubMed Web of Science ®Google Scholar
• Menkes D. B., Rasenick M. M., Wheeler M. A., Bitensky M. W. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long‐term antidepressant treatment. Science 1983; 129: 65–7
   Google Scholar
• Ozawa H., Rasenick M. M. Chronic electroconvulsive treatment augments coupling of the GTP‐binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem 1991; 56: 330–8
   PubMed Web of Science ®Google Scholar
• Perez J., Tinelli D., Brunello N., Racagni G. cAMP‐dependent phosphorylation of soluble and crude microtubule fractions of rat cerebral cortex after prolonged desmethylimipramine treatment. Eur J Pharmacol 1989; 172: 305–16
   PubMed Web of Science ®Google Scholar
• Nestler E., Terwilliger R. Z., Duman R. S. Chronic antidepressant administration alters the subcellular distribution of cAMP‐dependent protein kinase in rat frontal cortex. J Neurochem 1989; 53: 1644–7
   PubMed Web of Science ®Google Scholar
• Ye Y., Conti M., Houslay M. D., Faroqui S. M., Chen M., O'Donnell J. M. Noradrenergic activity differentially regulates the expression of rolipram‐sensitive, high‐affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 1997; 69: 2397–404
   Google Scholar
• Takahashi M., Terwilliger R., Lane S., Mezes P. S., Conti M., Duman R. S. Chronic antidepressant administration increases the expression of cAMP phosphodiesterase 4A and 4B isoforms. J Neurosci 1999; 19: 610–18
   Google Scholar
• Nibuya M., Nestler E. J., Duman R. S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365–72
   PubMed Web of Science ®Google Scholar
• Fujimaki K., Morinobu S., Duman R. S. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant‐induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology 2000; 22: 42–51
   PubMed Web of Science ®Google Scholar
• Gould T. D., Quiroz J. A., Singh J., Zarate C. A., Manji H. K. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004; 9: 734–55
   PubMed Web of Science ®Google Scholar
• Chen G., Manji H. K., Wright C. B., Hawver D. B., Potter W. Z. Effects of valproic acid on beta‐adrenergic receptors, G‐proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996; 15: 271–80
   PubMed Web of Science ®Google Scholar
• Chen G., Pan B., Hawver D. B., Wright C. B., Potter W. Z., Manji H. K. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996; 67: 2079–86
   PubMed Web of Science ®Google Scholar
• Deogracias R., Espliguero G., Iglesias T., Rodriguez‐Pena A. Expression of the neurotrophin receptor trkB is regulated by the cAMP/CREB pathway in neurons. Mol Cell Neurosci 2004; 26: 470–80
   Google Scholar
• Fukuchi M., Tabuchi A., Tsuda M. Transcriptional regulation of neuronal genes and its effect on neural functions: cumulative mRNA expression of PACAP and BDNF genes controlled by calcium and cAMP signals in neurons. J Pharmacol Sci 2005; 98: 212–18
   Google Scholar
• McCauslin C. S., Heath V., Colangelo A. M., Malik R., Lee S., Mallei A., et al. CAAT/Enhancer‐binding Protein {delta} and cAMP‐response Element‐binding Protein Mediate Inducible Expression of the Nerve Growth Factor Gene in the Central Nervous System. J Biol Chem 2006; 281: 17681–8
   PubMed Web of Science ®Google Scholar
• Thomas M. J., Umayahara Y., Shu H., Centrella M., Rotwein P., McCarthy T. L. Identification of the cAMP response element that controls transcriptional activation of the insulin‐like growth factor‐I gene by prostaglandin E2 in osteoblasts. J Biol Chem 1996; 271: 21835–41
   PubMedGoogle Scholar
• Tanimoto K., Yoshida E., Mita S., Nibu Y., Murakami K., Fukamizu A. Human activin betaA gene. Identification of novel 5' exon, functional promoter, and enhancers. J Biol Chem 1996; 271: 32760–9
   Google Scholar
• Pugazhenthi S., Miller E., Sable C., Young P., Heidenreich K. A., Boxer L. M., et al. Insulin‐like growth factor‐I induces bcl‐2 promoter through the transcription factor cAMP‐response element‐binding protein. J Biol Chem 1999; 274: 27529–35
   PubMed Web of Science ®Google Scholar
• Jeon S. H., Seong Y. S., Juhnn Y. S., Kang U. G., Ha K. S., Kim Y. S., et al. Electroconvulsive shock increases the phosphorylation of cyclic AMP response element binding protein at Ser‐133 in rat hippocampus but not in cerebellum. Neuropharmacology 1997; 36: 411–4
   Google Scholar
• Thome J., Sakai N., Shin K. H., Steffen C., Zhang Y‐J., Impey S., et al. cAMP response element‐mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030–6
   PubMed Web of Science ®Google Scholar
• Chen A‐H., Shirayama Y., Shin K‐H., Neve R. L., Duman R. S. Expression of the cAMP response element binding protein (CREB) in hippocampus produces antidepressant effect. Biol Psychiatry 2001; 49: 753–62
   PubMed Web of Science ®Google Scholar
• Tiraboschi E., Tardito D., Kasahara J., Moraschi S., Pruneri P., Gennarelli M., et al. Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology 2004; 29: 1831–40
   PubMed Web of Science ®Google Scholar
• Alt A., Nisenbaum E. S., Bleakman D., Witkin J. M. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006; 71: 1273–88
   PubMed Web of Science ®Google Scholar
• Svenningsson P., Tzavara E. T., Liu F., Fienberg A. A., Nomikos G. G., Greengard P. DARPP‐32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci U S A 2002; 99: 3188–93
   PubMed Web of Science ®Google Scholar
• Svenningsson P., Tzavara E. T., Witkin J. M., Fienberg A. A., Nomikos G. G., Greengard P. Involvement of striatal and extrastriatal DARPP‐32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci U S A 2002; 99: 3182–7
   PubMed Web of Science ®Google Scholar
• Newton S. S., Thome J., Wallace T. L., Shirayama Y., Schlesinger L., Sakai N., et al. Inhibition of cAMP response element‐binding protein or dynorphin in the nucleus accumbens produces an antidepressant‐like effect. J Neurosci 2002; 22: 10883–90
   PubMed Web of Science ®Google Scholar
• Pliakas A., Carlson R. R., Neve R. L., Konradi C., Nestler E. J., Carlezon W. A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated CREB expression in the nucleus accumbens. J Neurosci 2001; 21: 7397–403
   PubMed Web of Science ®Google Scholar
• Duman R. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004; 5: 11–25
   PubMed Web of Science ®Google Scholar
• Dwivedi Y., Rizavi H. S., Conley R. R., Pandey G. N. ERK MAP kinase signaling in post‐mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf‐1 and B‐Raf. Mol Psychiatry 2006; 11: 86–98
   PubMedGoogle Scholar
• Dwivedi Y., Rizavi H. S., Roberts R. C., Conley R. C., Tamminga C. A., Pandey G. N. Reduced activation and expression of ERK1/2 MAP kinase in the post‐mortem brain of depressed suicide subjects. J Neurochem 2001; 77: 916–28
   PubMed Web of Science ®Google Scholar
• Karege F., Vaudan G., Schwald M., Perroud N., La Harpe R. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136: 29–37
   PubMedGoogle Scholar
• Mercier G., Lennon A. M., Renouf B., Dessouroux A., Ramauge M., Courtin F., et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004; 24: 207–16
   PubMed Web of Science ®Google Scholar
• Kodama M., Russell D. S., Duman R. S. Electroconvulsive seizures increase the expression of MAP kinase phosphatases in limbic regions of rat brain. Neuropsychopharm 2005; 30: 360–71
   Google Scholar
• Bhat R. V., Engber T. M., Finn J. P., Koury E. J., Contreras P. C., Miller M. S., et al. Region‐specific targets of p42/p44MAPK signaling in rat brain. J Neurochem 1998; 70: 558–71
   Google Scholar
• Einat H., Yuan P., Gould T. D., Li j., Du J., Zhang L., et al. The role of the extracellular signal‐regulated kinase signaling pathway in mood modulation. J Neurosci 2003; 23: 7311–16
   PubMed Web of Science ®Google Scholar
• Hao Y., Creson T., Zhang L., Li P., Yuan P., Gould T. D., et al. Mood stabilizer valproate promotes ERK pathway‐dependent cortical neuronal growth and neurogenesis. J Neurosci 2004; 24: 6590–9
   PubMed Web of Science ®Google Scholar
• Yuan P., Juong L. D., Jiang Y. M., Gutkind J. S., Manji H. K., Chen G. The mood‐stabilizer valproic acid activates mitogen‐activated protein kinases and promotes neurite growth. J Biol Chem 2001; 19: 19
   Google Scholar
• Duman C. H., Schlesinger L., Kodama M., Russell D. S., Duman R. S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 2007; 61: 661–70
   PubMed Web of Science ®Google Scholar
• Dwivedi Y., Rizavi H. S., Conley R. R., Roberts R. C., Tamminga C. A., Pandey G. N. Altered gene expression of brain‐derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804–15
   PubMed Web of Science ®Google Scholar
• Karege F., Perret G., Bondolfi G., Schwald M., Bertschy G., Aubry J. M. Decreased serum brain‐derived neurotrophic factor levels in major depressed patients. Psychiatry Res 2002; 109: 143–8
   PubMed Web of Science ®Google Scholar
• Shimizu E., Hashimoto K., Okamura N., Koike K., Komatsu N., Kumakiri C., et al. Alterations of serum levels of brain‐derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54: 70–5
   PubMed Web of Science ®Google Scholar
• Evans S., Choudary P. V., Neal C. R., Li J. Z., Vawter M. P., Tomita H., et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 2004; 101: 15506–11
   PubMed Web of Science ®Google Scholar
• Ueyama T., Kawai Y., Nemoto K., Sekimoto M., Tone S., Senba E. Immobilization stress reduced the expression of neurotrophins and their receptors in the rat brain. Neurosci Research 1997; 28: 103–10
   PubMed Web of Science ®Google Scholar
• Heine V., Zareno J., Maslam S., Joels M., Lucassen P. J. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk‐1 protein expression. Eur J Neurosci 2005; 21: 1304–14
   PubMed Web of Science ®Google Scholar
• Newton S., Collier E., Hunsberger J., Adams D., Salvanayagam E., Duman R. S. Gene profile of electroconvulsive seizures: induction of neurogenic and angiogenic factors. J Neurosci 2003; 23: 10841–51
   PubMed Web of Science ®Google Scholar
• Altar C. A., Laeng P., Jurata L. W., Brockman J. A., Lemire A., Bullard J., et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 2004; 24: 2667–77
   PubMed Web of Science ®Google Scholar
• Warner‐Schmidt J. L., Duman R. S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A 2007; 104: 4647–52
   PubMed Web of Science ®Google Scholar
• Dow A. L., Russell D. S., Duman R. S. Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models. J Neurosci 2005; 25: 4908–16
   Google Scholar
• Khawaja X., Xu J., Liang J. J., Barrett J. E. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. J Neurosci Res 2004; 75: 451–60
   PubMed Web of Science ®Google Scholar
• Mallei A., Shi B., Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol Pharmacol 2002; 61: 1017–24
   PubMed Web of Science ®Google Scholar
• Gonul A. S., Akdeniz F., Taneli F., Donat O., Eker C., Vahip S. Effect of treatment on serum brain‐derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci 2005; 255: 381–6
   PubMed Web of Science ®Google Scholar
• Chen B., Dowlatshahi D., MacQueen G. M., Wang J‐F., Young L. T. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260–5
   PubMed Web of Science ®Google Scholar
• Aydemir O., Deveci A., Taneli F. The effect of chronic antidepressant treatment on serum brain‐derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psych 2004; 29: 261–5
   Google Scholar
• Gervasoni N., Aubrey J. M., Bondolfi G., Osiek G., Schwald M., Bertschv G., et al. Partial normalization of serum brain‐derived neurotrophic factor in remitted patients after a major depressive episode. Neuropsychobiology 2005; 51: 234–8
   PubMed Web of Science ®Google Scholar
• Fukumoto T., Morinobu S., Okamoto Y., Kagaya A., Yamawaki S. Chronic lithium treatment increases the expression of brain‐derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001; 158: 100–6
   PubMed Web of Science ®Google Scholar
• Duman R., Monteggia L. M. A neurotrophic model for stress‐related mood disorders. Biol Psychiatry 2006; 59: 1116–27
   PubMed Web of Science ®Google Scholar
• Berton O., McClung C. A., Dileone R. J., Krishnan V., Renthal W., Russo S. J., et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 311: 864–8
   PubMed Web of Science ®Google Scholar
• Eisch A. J., Bolanos C. A., de Wit J., Simonak R. D., Pudiak C. M., Barrot M., et al. Brain‐derived neurotrophic factor in the ventral midbrain‐nucleus accumbens pathway: a role in depression. Biol Psychiatry 2003; 54: 994–1005
   PubMed Web of Science ®Google Scholar
• Shirayama Y., Chen A. C., Nakagawa S., Russell D. S., Duman R. S. Brain‐derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251–61
   PubMed Web of Science ®Google Scholar
• Warner J., Duman R. S. Vascular endothelial growth factor mediates antidepressant‐induced neurogenesis. Soc Neurosci Abstract 2005
   Google Scholar
• Hoshaw B. A., Malberg J. E., Lucki I. Central administration of IGF‐I and BDNF leads to long‐lasting antidepressant‐like effects. Brain Res 2005; 1037: 204–8
   PubMed Web of Science ®Google Scholar
• Conti A. C., Cryan J. F., Dalvi A., Lucki I., Blendy J. A. cAMP response element‐binding protein is essential for the upregulation of brain‐derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci 2002; 22: 3262–8
   PubMed Web of Science ®Google Scholar
• Farooq A., Zhou M. M. Structure and regulation of MAPK phosphatases. Cell Signal 2004; 16: 769–79
   PubMed Web of Science ®Google Scholar
• Theodosiou A., Ashworth A. MAP kinase phosphatases. Genome Biol 2002; 3: REVIEWS3009
   PubMed Web of Science ®Google Scholar
• Keyse S. M. Protein phosphatases and the regulation of mitogen‐activated protein kinase signalling. Curr Opin Cell Biol 2000; 12: 186–92
   PubMed Web of Science ®Google Scholar
• Canettieri G., Morantte I., Guzman E., Asahara H., Herzig S., Anderson S. D., et al. Attenuation of a phosphorylation‐dependent activator by an HDAC‐PP1 complex. Nat Struct Biol 2003; 10: 175–81
   PubMedGoogle Scholar
• Huang E., Reichardt L. F. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem 2003; 72: 609–42
   PubMed Web of Science ®Google Scholar
• Rhee S. G. Regulation of phosphoinositide‐specific phospholipase C. Annu Rev Biochem 2001; 70: 281–312
   PubMed Web of Science ®Google Scholar
• Battaini F. Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol Res 2001; 44: 353–61
   PubMed Web of Science ®Google Scholar
• Keenan C., Kelleher D. Protein kinase C and the cytoskeleton. Cell Signal 1998; 10: 225–32
   PubMed Web of Science ®Google Scholar
• Allison J. H., Stewart M. A. Reduced brain inositol in lithium‐treated rats. Nat New Biol 1971; 233: 267–8
   PubMedGoogle Scholar
• Allison J. H., Blisner M. E., Holland W. H., Hipps P. P., Sherman W. R. Increased brain myo‐inositol 1‐phosphate in lithium‐treated rats. Biochem Biophys Res Commun 1976; 71: 664–70
   PubMed Web of Science ®Google Scholar
• Moore G. J., Bebchuk J. M., Parrish J. K., Faulk M. W., Arfken C. L., Strahl‐Bevacqua J., et al. Temporal dissociation between lithium‐induced changes in frontal lobe myo‐inositol and clinical response in manic‐depressive illness. Am J Psychiatry 1999; 156: 1902–8
   PubMed Web of Science ®Google Scholar
• O'Donnell T., Rotzinger S., Nakashima T. T., Hanstock C. C., Ulrich M., Silverstone P. H. Chronic lithium and sodium valproate both decrease the concentration of myo‐inositol and increase the concentration of inositol monophosphates in rat brain. Brain Res 2000; 880: 84–91
   PubMed Web of Science ®Google Scholar
• Wolfson M., Hertz E., Belmaker R. H., Hertz L. Chronic treatment with lithium and pretreatment with excess inositol reduce inositol pool size in astrocytes by different mechanisms. Brain Res 1998; 787: 34–40
   PubMed Web of Science ®Google Scholar
• Williams R., Cheng L., Mudge A. W., Harwood A. J. A common mechanism of action for three mood‐stabilizing drugs. Nature 2002; 417: 292–5
   PubMed Web of Science ®Google Scholar
• Shamir A., Shaltiel G., Greenberg M. L., Belmaker R. H., Agam G. The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse hippocampus; a comparison with the yeast model. Brain Res Mol Brain Res 2003; 115: 104–10
   PubMedGoogle Scholar
• Harwood A. J. Lithium and bipolar mood disorder: the inositol‐depletion hypothesis revisited. Mol Psychiatry 2005; 10: 117–26
   PubMed Web of Science ®Google Scholar
• Wang H. Y., Johnson G. P., Friedman E. Lithium treatment inhibits protein kinase C translocation in rat brain cortex. Psychopharmacology (Berl) 2001; 158: 80–6
   PubMed Web of Science ®Google Scholar
• Wang H., Friedman E. Increased association of brain protein kinase C with the receptor for activated C kinase‐1 (RACK1) in bipolar affective disorder. Biol Psychiatry 2001; 50: 364–70
   Google Scholar
• Lenox R. H., Watson D. G., Patel J., Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992; 570: 333–40
   PubMedGoogle Scholar
• Manji H. K., Etcheberrigaray R., Chen G., Olds J. L. Lithium decreases membrane‐associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303–10
   PubMedGoogle Scholar
• Manji H. K., Bersudsky Y., Chen G., Belmaker R. H., Potter W. Z. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo‐inositol. Neuropsychopharmacology 1996; 15: 370–81
   PubMed Web of Science ®Google Scholar
• Manji H. K., Lenox R. H. Ziskind‐Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic‐depressive illness. Biol Psychiatry 1999; 46: 1328–51
   PubMed Web of Science ®Google Scholar
• Gould T., Manji H. K. Glycogen synthase kinase‐3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005; 30: 1223–37
   PubMed Web of Science ®Google Scholar
• Watcharasit P., Bijur G. N., Zmijewski J. W., Song L., Zmijewska A., Chen X., et al. Direct, activating interaction between glycogen synthase kinase‐3beta and p53 after DNA damage. Proc Natl Acad Sci U S A 2002; 99: 7951–5
   PubMed Web of Science ®Google Scholar
• Linseman D. A., Butts B. D., Precht T. A., Phelps R. A., Le S. S., Laessig T. A., et al. Glycogen synthase kinase‐3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 2004; 24: 9993–10002
   PubMed Web of Science ®Google Scholar
• Grimes C. A., Jope R. S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391–426
   PubMed Web of Science ®Google Scholar
• Grimes C. A., Jope R. S. CREB DNA binding activity is inhibited by glycogen synthase kinase‐3 beta and facilitated by lithium. J Neurochem 2001; 78: 1219–32
   PubMed Web of Science ®Google Scholar
• Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M. D. Cellular function of phosphoinositide 3‐kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17: 615–75
   PubMed Web of Science ®Google Scholar
• Raymond J. R., Mukhin Y. V., Gelasco A., Turner J., Collinsworth G., Gettys T. W., et al. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001; 92: 179–212
   PubMed Web of Science ®Google Scholar
• Bennecib M., Gong C. X., Grundke‐Iqbal I., Iqbal K. Role of protein phosphatase‐2A and ‐1 in the regulation of GSK‐3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett 2000; 485: 87–93
   PubMed Web of Science ®Google Scholar
• Klein P., Melton D. A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996; 93: 8455–9
   PubMed Web of Science ®Google Scholar
• Stambolic V., Ruel L., Woodgett J. R. Lithium inhibits glycogen synthase kinase‐3 activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664–8
   PubMed Web of Science ®Google Scholar
• De Sarno P., Li X., Jope R. S. Regulation of Akt and glycogen synthase kinase‐3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158–64
   PubMed Web of Science ®Google Scholar
• Kirshenboim N., Plotkin B., Shlomo S. B., Kaidanovich‐Beilin O., Eldar‐Finkelman H. Lithium‐mediated phosphorylation of glycogen synthase kinase‐3beta involves PI3 kinase‐dependent activation of protein kinase C‐alpha. J Mol Neurosci 2004; 24: 237–45
   PubMedGoogle Scholar
• Chalecka‐Franaszek E., Chuang D. M. Lithium activates the serine/threonine kinase Akt‐1 and suppresses glutamate‐induced inhibition of Akt‐1 activity in neurons. Proc Natl Acad Sci U S A 1999; 96: 8745–50
   PubMed Web of Science ®Google Scholar
• Gould T. D., Chen G., Manji H. K. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase‐3. Neuropsychopharmacology 2004; 29: 32–8
   PubMed Web of Science ®Google Scholar
• Chen G., Huang L. D., Jiang Y. M., Manji H. K. The mood‐stabilizing agent valproate inhibits the activity of glycogen synthase kinase‐3. J Neurochem 1999; 72: 1327–30
   PubMed Web of Science ®Google Scholar
• Hall A. C., Brennan A., Goold R. G., Cleverley K., Lucas F. R., Gordon‐Weeks P. R., et al. Valproate regulates GSK‐3‐mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci 2002; 20: 257–70
   PubMed Web of Science ®Google Scholar
• Roh M. S., Eom T. Y., Zmijewska A. A., De Sarno P., Roth K. A., Jope R. S. Hypoxia activates glycogen synthase kinase‐3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry 2005; 57: 278–86
   PubMed Web of Science ®Google Scholar
• Li X., Zhu W., Roh M. S., Friedman A. B., Rosborough K., Jope R. S. In vivo regulation of glycogen synthase kinase‐3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29: 1426–31
   PubMed Web of Science ®Google Scholar
• Madsen T. M., Newton S. S., Eaton M. E., Russell D. S., Duman R. S. Chronic electroconvulsive seizure up‐regulates beta‐catenin expression in rat hippocampus: role in adult neurogenesis. Biol Psychiatry 2003; 54: 1006–14
   PubMed Web of Science ®Google Scholar
• Kang U. G., Roh M. S., Jung J. R., Shin S. Y., Lee Y. H., Park J. B., et al. Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 41–4
   PubMedGoogle Scholar
• Roh M. S., Kang U. G., Shin S. Y., Lee Y. H., Jung H. Y., Juhnn Y. S., et al. Biphasic changes in the Ser‐9 phosphorylation of glycogen synthase kinase‐3beta after electroconvulsive shock in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1–5
   PubMedGoogle Scholar
• Alimohamad H., Rajakumar N., Seah Y. H., Rushlow W. Antipsychotics alter the protein expression levels of beta‐catenin and GSK‐3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry 2005; 57: 533–42
   PubMed Web of Science ®Google Scholar
• Emamian E. S., Hall D., Birnbaum M. J., Karayiorgou M., Gogos J. A. Convergent evidence for impaired AKT1‐GSK3beta signaling in schizophrenia. Nat Genet 2004; 36: 131–7
   PubMed Web of Science ®Google Scholar
• Kaidanovich‐Beilin O., Milman A., Weizman A., Pick C. G., Eldar‐Finkelman H. Rapid antidepressive‐like activity of specific glycogen synthase kinase‐3 inhibitor and its effect on beta‐catenin in mouse hippocampus. Biol Psychiatry 2004; 55: 781–4
   PubMed Web of Science ®Google Scholar
• Gould T. D., Einat H., Bhat R., Manji H. K. AR‐A014418, a selective GSK‐3 inhibitor, produces antidepressant‐like effects in the forced swim test. Int J Neuropsychopharmacol 2004; 7: 387–90
   PubMed Web of Science ®Google Scholar
• O'Brien W. T., Harper A. D., Jove F., Woodgett J. R., Maretto S., Piccolo S., et al. Glycogen synthase kinase‐3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 2004; 24: 6791–8
   PubMed Web of Science ®Google Scholar
• Beaulieu J. M., Sotnikova T. D., Yao W. D., Kockeritz L., Woodgett J. R., Gainetdinov R. R., et al. Lithium antagonizes dopamine‐dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004; 101: 5099–104
   PubMed Web of Science ®Google Scholar
• Jeon Y. H., Heo Y. S., Kim C. M., Hyun Y. L., Lee T. G., Ro S., et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005; 62: 1198–220
   PubMed Web of Science ®Google Scholar
• Tsankova N. M., Berton O., Renthal W., Kumar A., Neve R. L., Nestler E. J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006; 9: 519–25
   PubMed Web of Science ®Google Scholar
• Phiel C. J., Zhang F., Huang E. Y., Guenther M. G., Lazar M. A., Klein P. S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734–41
   PubMed Web of Science ®Google Scholar
• Bebchuk J. M., Arfken C. L., Dolan‐Manji S., Murphy J., Hasanat K., Manji H. K. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000; 57: 95–7
   PubMed Web of Science ®Google Scholar
• Bhat R. V., Budd Haeberlein S. L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313–7
   PubMed Web of Science ®Google Scholar
• Gould T. D., Zarate C. A., Manji H. K. Glycogen synthase kinase‐3: a target for novel bipolar disorder treatments. J Clin Psychiatry 2004; 65: 10–21
   PubMed Web of Science ®Google Scholar
• Tanis K. Q., Newton S. S., Duman R. S. Targeting neurotrophic/growth factor expression and signaling for antidepressant drug development. CNS Neurol Disord Drug Targets 2007; 6: 151–60
   PubMedGoogle Scholar